Please assess the completion status of the following clinical trial:

Trial Title: Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years.~* Creatinine clearance ≤ 60 ml/min by the Cockcroft-Gault equation~* Patients not anticipated to go on dialysis or have renal transplantation in the next 6 months~* Ability to provide informed consent~* Life expectancy greater than 12 months~Exclusion Criteria:~* Diabetes mellitus or a fasting blood glucose ≥ 110 mg/dL~* Acute renal failure~* Class 3 or 4 heart failure~* Liver failure, ascites, or an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) two times the upper limit of normal~* Hemoglobin less than 9 mg/dL~* Multiple myeloma~* Premenopausal women not using at least 1 form of birth control~* Pregnant or nursing women~* Prisoners~* Known allergy to pioglitazone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
- Pioglitazone (Type: ACTIVE_COMPARATOR): Pioglitazone 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.

Based on this trial design, predict the completion outcome and termination type (if applicable).